> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Info Collection on User Fee Program Evaluation
- URL: https://www.fdaweb.com/info-collection-on-user-fee-program-evaluation/
- Published: 2022-03-18T12:00:00.000Z
- Updated: 2026-09-14T17:37:07.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151400

*Federal Register* notice: FDA is seeking comments on an information collection extension entitled “Evaluation of the Program for Enhanced Review Transparency and Communication for New Molecular Entity New Drug Applications and Original 351(a) Biologics License Applications in Prescription Drug User Fee Acts and 351(k) Biologics License Applications in Biosimilar User Fee Acts” (OMB Control Number 0910-0746). The collection is intended to support the evaluation of certain performance goals and procedures set forth in what is known as FDA’s “goals letter” or “commitment letter” under the sixth authorization of the Prescription Drug User Fee Act (PDUFA VI) and the second authorization of the Biosimilar User Fee Act (BsUFA II). To view the notice, click [here](https://public-inspection.federalregister.gov/2022-05814.pdf?ref=fdaweb.com).